Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that... | December 1, 2021
United States France General Hartmutj Ehrlich European Medicines Agency Drug Administration Euronext Paris
Source: marketscreener.com